Citigroup maintains a "Buy" rating for Arcus Biosciences, Inc. (NYSE:RCUS) despite adjusting its price target from $56 to$44 following the discontinuation of the Phase 3 STAR-221 study.The STAR-221 study's discontinuation, due to lack of improved overall survival rates in cancer treatment, has led to a significant stock price decline of approximately 14.38%.Arcus Biosciences continues its research and development efforts, focusing on its inflammation and immunology portfolio despite recent setbacks.Arcus B ...